NCT05510908 · OUTCOME

Proportion of Participants Eligible for AMC Trials Who Are Successfully Enrolled

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC · Source last updated 2026-08-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of enrolled in AMC studies
Interval / dispersion: Not reported
Time frame: Baseline

What was measured

This will be calculated by the number of participants enrolled who meet site-based AMC trial eligibility compared to the number of eligible participants at each site who meet site-based AMC trial eligibility.

Analysis population: The participants who are eligible to meet site-based AMC trial eligibility

Groups in this outcome

New, Primary or Recurrent Disease

Considering or currently receiving cancer treatment Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.

Metastic or Locally Advanced Cancer

This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.

Prior Cancer

Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
New, Primary or Recurrent Disease	20
Metastic or Locally Advanced Cancer	2
Prior Cancer	4

Reported measurements

Source class 1

Values in percentage of enrolled in AMC studies · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
New, Primary or Recurrent Disease	40	Not reported	Not reported	Not reported	Not reported
Metastic or Locally Advanced Cancer	50	Not reported	Not reported	Not reported	Not reported
Prior Cancer	50	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
40
group Id
OG001
value
50
group Id
OG002
value
50

denoms

counts
group Id
OG000
value
20
group Id
OG001
value
2
group Id
OG002
value
4
units
Participants

description

groups

description
Considering or currently receiving cancer treatment Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
id
OG000
title
New, Primary or Recurrent Disease
description
This includes cases for which there are no current definitive therapy options for cure (i.e., inoperable) but may be considered for non-standard / non-curative therapies. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review. Non-Interventional Follow-up: Participants initiating or receiving ongoing treatment for their cancer will attend a single follow-up visit to recollect broad demographic and clinical data. Data collection at study visits will occur via survey procedures and/or medical record review.
id
OG001
title
Metastic or Locally Advanced Cancer
description
Prior diagnosis (within 5 years), in remission - Not currently on cancer treatment other than ART or maintenance therapy. Non-Interventional: Participants will be identified via screening of electronic medical records or institutional databases. All eligible participants will have one visit for the collection of broad demographic and clinical data. Data collection at study visit will occur via survey procedures and/or medical record review.
id
OG002
title
Prior Cancer

param Type

NUMBER

population Description

The participants who are eligible to meet site-based AMC trial eligibility

reporting Status

POSTED

time Frame

Baseline

title

Proportion of Participants Eligible for AMC Trials Who Are Successfully Enrolled

type

SECONDARY

unit Of Measure

percentage of enrolled in AMC studies

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice